United States · Platforms & data · MarketBeat

Arrowhead Pharmaceuticals Q4 Earnings Call Highlights

Published by MarketBeat · United States 3 h ago

Image from MarketBeat Media, LLC. · MarketBeat

Detailed summary

Arrowhead Pharmaceuticals (NASDAQ:ARWR) is preparing for a potential U.S. launch of its drug REDEMPLO in a larger patient population in the second quarter of 2027, as the company works to turn growing prescription demand for the medicine into paid treatments. On its fiscal 2026 earnings call, manag

Read the full article on MarketBeat Sign in to save

MarketNews shows the headline and summary published by the outlet. The full article is on the publisher's website. (www.marketbeat.com)

Also worth reading

Seeking Alpha

Who can replace Jensen Huang as Nvidia CEO? These four names are buzzing in AI circles.

Stocktwits

S&P 500, Dow, Nasdaq Futures Recover After Markets End Lower On Jensen Huang’s Exit, Oil Price Pressure — CRWV, CBRS, NVDA, TSLA In Focus

Yahoo Finance

Arrowhead Pharmaceuticals Q4 Earnings Call Highlights

Detailed summary

Share

Also worth reading

Recruit Holdings GAAP EPS of ¥159.54, revenue of ¥1.09T

How the Jensen Huang affair changes the outlook for U.S.-China relations

Matador Resources chairman and CEO buys $123,225 in stock

Who can replace Jensen Huang as Nvidia CEO? These four names are buzzing in AI circles.

S&P 500, Dow, Nasdaq Futures Recover After Markets End Lower On Jensen Huang’s Exit, Oil Price Pressure — CRWV, CBRS, NVDA, TSLA In Focus

Treasury Bonds Now Pay More Than Stocks Earn by a Gap Last Seen in 2009. Warren Buffett Warned in 1999 What That Does to Stock Prices